Background Nirmatrelvir–ritonavir has been authorized for emergency use by many
countries for the treatment of coronavirus disease 2019 (Covid-19). However, the supply …

Introduction Early reports showed that Omicron (BA. 1) SARS-CoV-2 could be less severe.
However, the magnitude of risk reduction of hospitalization and mortality of Omicron (BA. 1) …

Summary Background The SARS-CoV-2 omicron variant of concern was identified in South
Africa in November, 2021, and was associated with an increase in COVID-19 cases. We …

Abstract The Omicron B. 1.1. 529 SARS-CoV-2 variant was first detected in late November
2021 and has since spread to multiple countries worldwide. We model the potential …

Importance The SARS-CoV-2 Omicron subvariant, BA. 2, may be less severe than previous
variants; however, confounding factors make interpreting the intrinsic severity challenging …

This retrospective multi-center matched cohort study assessed the risk for severe COVID-19
(combination of severity indicators), intensive care unit (ICU) admission, and in-hospital …

Challenges in Inferring Omicron's Severity Omicron's spread in South Africa has led to fewer
hospitalizations and deaths per documented case than were seen during previous waves …

The spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the
major antigen stimulating the host's protective immune response. Here we assessed the …

Background The omicron variant (B. 1.1. 529) of SARS-CoV-2 has demonstrated partial
vaccine escape and high transmissibility, with early studies indicating lower severity of …

The world is in the midst of an unprecedented surge in SARS-CoV-2 cases attributable to
the Omicron variant. This new variant is 2 to 3 times more contagious than the Delta variant …